Neurofit Participates in 'K-HOSPITAL FAIR'... Introducing Brain Imaging Analysis AI Solution

[Asia Economy Reporter Hyunseok Yoo] Neurophet, a specialized company in artificial intelligence (AI) solutions for brain diseases, announced on the 6th that it participated in the ‘International Hospital and Medical Device Industry Fair (K-HOSPITAL FAIR 2021)’ and showcased various brain imaging analysis AI solutions.

The K-HOSPITAL FAIR, held over three days from the 30th of last month, is an international hospital and medical device industry exhibition introducing the latest medical trends. This year, more than 180 companies and over 30 institutions participated, with exhibitions held at more than 450 booths.

Through this fair, Neurophet introduced ▲brain imaging analysis solution ‘Neurophet AQUA’ ▲cloud-based brain imaging analysis AI platform ‘Neurophet SegPlus’, and ▲brain imaging treatment planning software ‘Neurophet tES LAB’.

‘Neurophet AQUA’ is a brain imaging analysis solution that analyzes brain atrophy and white matter degeneration related to neurodegenerative diseases (such as Alzheimer’s disease and stroke) using patients’ brain magnetic resonance imaging (MRI). By applying the core technology ‘Neurophet SegEngine’, MRI segmentation and analysis can be completed within one minute regardless of race, age, or gender. In March, ‘Neurophet AQUA’ received Class 2 medical device certification from the Ministry of Food and Drug Safety.

The brain imaging analysis AI platform ‘Neurophet SegPlus’ is a cloud-based AI analysis platform for brain imaging analysis. Existing brain imaging analysis programs used in neuroscience research are difficult to install and require more than a day for analysis. ‘SegPlus’ offers a fully automated process through an advanced AI engine, enabling brain imaging analysis to be completed in just three minutes.

‘Neurophet tES LAB’ is software that reconstructs the actual brain into a similar computer brain model using brain MRI and calculates the electric field distribution generated during electrical stimulation considering brain structure. It can accurately analyze the brain stimulation area and intensity, enabling patient-customized treatment through precise stimulation. ‘Neurophet tES LAB’ was the first in Korea to receive brain imaging treatment planning software certification from the Ministry of Food and Drug Safety.

Jungil Bin, CEO of Neurophet, said, “At the ‘K-HOSPITAL FAIR’, Neurophet’s brain imaging analysis AI solutions received enthusiastic responses and praise from participants and medical staff,” and added, “We will do our best to become a leading company in brain imaging analysis AI technology through continuous research and development.”